Search
Demecarium
go.drugbank.com/drugs/DB00944ApprovedDemecarium is an indirect-acting parasympathomimetic agent that is used to treat glaucoma. It is a cholinesterase inhibitor or an anticholinesterase. … The outflow of the aqueous humor is facilitated, which leads to a reduction in intraocular pressure.
Pegvaliase
go.drugbank.com/drugs/DB12839ApprovedInvestigationalPhenylketonuria is a rare autosomal recessive disorder that is characterized by deficiency of the enzyme phenylalanine hydroxylase (PAH) [A33284] and affects about 1 in 10,000 to 15,000 people in the United … PAH deficiency and inability to break down an amino acid phenylalanine (Phe) leads to elevated blood phenylalanine concentrations and accumulation of neurotoxic Phe in the brain, causing chronic intellectual
Tauroursodeoxycholic acid
go.drugbank.com/drugs/DB08834ApprovedInvestigationalWithdrawn[A249080] Tauroursodeoxycholic acid is currently used in Europe to treat and prevent gallstones as a bile acid derivative. … Tauroursodeoxycholic acid, also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid [A249070] that is produced in humans at a low concentration.
Deoxycholic acid
go.drugbank.com/drugs/DB03619ApprovedInvestigationalDeoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that … In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity.
Choline salicylate
go.drugbank.com/drugs/DB14006ApprovedNutraceuticalThis drug is also a main ingredient in teething gels to relieve pains associated with tooth growth in the infant population [L2134]. … The UK government has regulated its use, due to toxicity in those under 16 years of age.
Givosiran
go.drugbank.com/drugs/DB15066Approved[L10202] It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder … [L10202] Givosiran represents an important step forward in the treatment of acute hepatic porphyria as it is the first approved pharmacotherapy for the prevention of acute attacks - previous strategies
Delgocitinib
go.drugbank.com/drugs/DB16133ApprovedInvestigationalAfter the first global approval in Japan,[A264693] delgocitinib was also approved by the European Commission on September 23, 2024. … [L51913] It works to reduce the inflammatory response in inflammatory skin disorders.[A264703] On July 23, 2025, delgocitinib was also granted approval by the FDA.[L53508]
Prilocaine
go.drugbank.com/drugs/DB00750ApprovedInvestigationalCurrently, it is used most often for infiltration anesthesia in dentistry. (From AMA Drug Evaluations Annual, 1992, p165)
Mixtures: LIDOCAINA E PRILOCAINA TEVA, LIDOCAINA E PRILOCAINA TEVASynonyms: alpha-n-Propylamino-2-methylpropionanilide, N-(2-Methylphenyl)-2-(propylamino)propanamideEfinaconazole
go.drugbank.com/drugs/DB09040ApprovedInvestigationalIt was approved for use in Canada and the USA in 2014 and is marketed by Valeant Pharmaceuticals North America LLC under the name Jublia. … Efinaconazole is a 14 alpha-demethylase inhibitor indicated in the treatment of fungal infection of the nail, known as onychomycosis.
Lithium cation
go.drugbank.com/drugs/DB01356ApprovedInvestigationalWithdrawnThe active principle in these salts is the lithium ion Li+, which having a smaller diameter, can easily displace K+ and Na+ and even Ca+2, in spite of its greater charge, occupying their sites in several … They are used in the treatment of bipolar disorder, since unlike most other mood altering drugs, they counteract both mania and depression.